Experimental combo for advanced tumors hits early hurdle

NCT ID NCT03968653

Terminated Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Debio 0123 (oral capsule) and carboplatin (IV infusion)
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This was a very early (phase 1) trial that was terminated, so results are limited. The combination may cause significant side effects and may not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Clinica Universidad de Navarra

Madrid, 28027, Spain
Clinica Universidad de Navarra - Pamplona

Pamplona, 31008, Spain
Hospital Universitario Virgen de la Victoria

Málaga, 29010, Spain
Hospital Vall Hebrón, Unidad de Investigación en Terapia Molecular (UITM)

Barcelona, 08035, Spain
Instituto Valenciano de Oncologia

Valencia, 46009, Spain
Leiden University Medical Center, Dept. of Clinical Oncology

Leiden, 2333, Netherlands
Radboud university medical center

Nijmegen, 6525, Netherlands
University Medical Center Groningen

Groningen, 9713, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.